I am responsible for leading the identification and evaluation of external licensing and partnering opportunities to strengthen AstraZeneca’s Oncology pipeline. I have a strong Oncology background, bringing technical and scientific expertise into external project evaluations, as well as leading Due Diligence teams. I was the iMED Strategy lead for several deals that successfully signed in 2013 including the in-licensing of Merck’s clinical Ph2 Wee1 kinase inhibitor, acquisition of ProBiodrug’s CDK9 program, the collaboration with Horizon for synthetic lethality screening, as well as supporting the Moderna deal to develop mRNA therapeutics.